Summary This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Drugs In Development, 2021, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 19, 17, 4, 46, 21 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
The ASEAN lifestyle-related disease supplements market studied was valued at USD 4,103.61 million in 2020, and it is projected to register a CAGR of 9.94% during the forecast period (2021-2026). The COVID-19 has increased the demand of various lifestyle-related disease supplements in the region on account of growing awareness and increasing...
The pen needles market is expected to reach USD 2.2 Billion by 2026 from an estimated USD 1.3 Billion in 2021, at a CAGR of 11.2%. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug...
The oxidative stress assay market is projected to reach USD 1,326 million by 2025 from USD 836 million in 2020, at a CAGR of 9.7%. Growth in the oxidative stress assay market can be attributed to growth in the biopharmaceutical industry and increasing public-sector funding for academic research. Other important factors aiding the growth of...
The major factors attributing to the growth of the biosurgery market are increasing geriatric population, rising prevalence of chronic diseases and related surgeries, and a strong focus on R&D leading to the launch of new and advanced products. The global increase in the number of geriatrics population and obese people is likely to...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
17 pages •
By Euromonitor International
• Dec 2020
Natural increase and modest net migration rates should drive population growth in South Africa in 2019-2040. While ageing will be rapid as birth rates decline and longevity rises, South Africa will remain a relatively young country in a global context. Its expanding workforce and increased prosperity should intensify consumer purchasing power...
The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020–2027. The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence...
98 pages •
By Infiniti Research Limited
• Jul 2016
About Hypercholesterolemia Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C....
70 pages •
By Infiniti Research Limited
• Mar 2017
About OCT OCT can help to identify diseases such as diabetic retinopathy and glaucoma at the granular level by providing the images of the retina in layers, which can help physicians identify the disease and form a treatment plan. Technavio’s analysts forecast the global OCT market to grow at a CAGR of 8.16% during...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.